On March 22, 2018, Parallax Advisors organized a conference about investment opportunities in healthcare.
AtonRâ Partners was one of the speakers and we presented the investment theme: Bionics.
When nature inspires the technology
Nature always inspired men and researchers for inventions and innovations. The dream of flying like a bird or swimming like a fish is as old as mankind itself. Leonardo Da Vinci, for example, centuries ago, attempted to exploit the principles of bird flight to design a flying machine.
This fascinating approach is motivated by the fact that evolutionary pressure typically forces living organisms to become highly optimized and efficient.
Most recent definitions of the term Bionics applied in medicine consider it simply as systems formed by merging biology, mechanics, and electronics to restore, or even enhance, the body functions.
We are living longer but not necessarily better
Today we are facing an aging population with 285 million people visually impaired, 360 million people with disabling hearing loss, 15% of the global population with a disability and more than 120,000 people in the US that are still waiting for a transplant.
The new generation is living longer but not necessarily better. They are more likely to be obese, have diabetes, or have high blood pressure than the previous generation at similar ages.
Moreover, chronic diseases and age-related degenerative diseases have increased too.
This overview gives to bionics a huge market opportunity and among all bionics technologies, synthetic biology, medical robots and wearable devices are the most interesting today considering the market size and the growth rate, and if we consider all technologies together, we are speaking about a global market of $113 billion by 2023.
Bionics technologies are no longer science fiction
Bionics technologies include devices that can help blind to see, give amputees new body parts and make paraplegic people walk again. But is not just this, bionics consists also in robotic surgery, artificial organs, wearable devices, DNA manipulation, 3D printing, artificial intelligence and virtual reality.
Engineering some devices that will have the same function as a natural part of the body or coordinate with natural processes is now a reality. Eyes are already in development, scientists are working on restoring the ability to create long-term memories by implanting chips in the brain, all limbs can now be replaced by artificial limbs giving hope to millions of people, transplants could become obsolete with Artificial Organs...
The future of medicine
Bionics also consists of wearable devices. These devices allow patients to keep a check on their conditions at home, like their glucose levels or their cardiac rhythm without the need to go to the physician. An example of wearable devices is the bionic pancreas. The bionic pancreas simulates the function of the real organ: regulate the blood glucose level. It is composed by two pumps, one containing the insulin and the other containing the glucagon. The insulin reduces the quantity of blood glucose and the glucagon does exactly the opposite. Then the sensor and the algorithm communicate to define the correct amount of glucagon and insulin to be injected by the pumps. This is the wearable device that better tries to simulate the pancreas.
Our modern lifestyle increases traumatic problems, pain, and joint damages. Some of today's robotic systems are collaborating with surgeons to perform complex procedures, like knee and hip surgeries, with more precision and control, giving also to the patient a better outcome, with smaller scares, a faster recovery, and less pain. The systems are robotic arms that give a feedback to the surgeon when he is doing something not in accordance with the planned surgery.
Nowadays, robotic surgery is also used for the spine, brain, and abdominal surgery. Concerning spine and brain, the robot just gives the surgeons the correct trajectory to insert the instruments.
Synthetic biology: the revolution begins...
Synthetic biology involves the transfer of genes from an organism to another to fabricate or redesign systems that do not exist in nature. We can, for example, replace defective genes with healthy ones, thus eliminating the cause of the disease. We can introduce genes that are able to inactivate defective genes and others.
This approach can be potentially used to eradicate tumors, genetic disorders, and viral infections. Today, gene editing is routinely used to introduce human genes inside bacteria to make them produce, low cost and rapidly, some medical substances like vaccines or insulin.
CAR-T cell therapy is an approach that consists of genetically modifying the immune cells, protecting us from exogenous organisms, to make cells much more receptive against some specific cancers.
But how do we replace defective genes or insert new ones? For example with CRISPR/Cas 9 system: This gene editing technology is used to make targeted changes to the genome of living cells.The CRISPR/Cas9 method can precisely modify, insert or delete disease-causing anomalies at their genetic sources. It has two components: a specific section of guide-RNA (CRISPR) and a “scissors’” enzyme that cut DNA (Cas9). When the modified guide-RNA finds the matching gene, Cas 9 cleaves the DNA at the targeted point. A strand of DNA with the desired sequence is inserted in the cut site.
This new technology has the potential to treat more than 6,000 diseases: genetic diseases, diabetes or muscular dystrophy by inserting the correct gene to produce the missing protein. It could also be used against more complex diseases, such as cancer by targeting the protein responsible for cell division or by producing killer T-cell able to destroy tumor cells.
Bionics: a real long-term investment
Our investment solution on this thematic is a long-only and actively managed certificate. We believe that Bionics benefits from long-term drivers:
By accessing this website ("Site") and any of its pages you expressly agree that you have read, understood and agree to be bound by the terms and conditions and the legal information contained herein. If you do not agree to the terms and conditions below, you should exit the Site now.
Access to the information contained on this Site may be subject to legal and regulatory restrictions applicable to user (by reason of user’s place of residence or domicile, nationality, or for any other reason). Persons concerned by such prohibitions should not enter the Site.
The contents of this Site are provided for information purposes only. Nothing contained on this Site constitutes a solicitation, an offer or a recommendation to purchase or sell any product and/or may be construed as an offer, an invitation or solicitation to enter into any specific transaction or strategy. None of the products mentioned on this Site are available and term sheet shall not be distributed to any person or entity in any jurisdiction or country where such distribution or use would be contrary to any applicable law or regulation.
The collective investment scheme (hereinafter referred to as the "Fund") referred to on this Site is registered only in Luxembourg.
The products mentioned on the Site may not be offered, sold, assigned, or delivered, directly or indirectly at any time by any “US person”. In particular, the Fund mentioned on the Site has not been nor will be registered under the Securities Act of 1933 in the USA.
Although AtonRâ Partners believes that the information is reliable when posted on the Site, it makes no representation or guarantee that it is accurate or complete.
The information and opinions contained on the Site are subject to change without notice.
AtonRâ Partners shall not be responsible or liable for any loss or damage of any nature whatsoever (including direct, indirect, incidental or consequential) arising out of or in connection with the access to or the use of, or any inability to access or to use any information or data on this Site, including without limitation in the event of negligence.
Unless expressly stated otherwise, all information available on this Site is protected by copyright, with all rights reserved. The elements may be used freely for navigation purposes only and must expressly mention AtonRâ Partners in the event of reproduction, in whole or in part, of such elements in any form whatsoever, including in written or electronic form. No part of this Site may be distributed or transmitted without the express consent of AtonRâ Partners. Links to the Site or use of the content for advertising or commercial purposes is subject to the prior written consent of AtonRâ Partners.
AtonRâ Partners places great importance on data protection and makes every effort to safeguard the privacy of information. However, the Internet, like other electronic information and communication systems, cannot guarantee absolute security.
Use of this Site is subject to the laws of Switzerland without reference to any conflict of law principles. The courts of Geneva, Switzerland, shall have exclusive jurisdiction over any claims or disputes arising out of or in connection with the Site and its use.